Carvicor

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carvicor

What is Carvicor?

Property Description
Active ingredient Carvedilol
Form Oral tablet or capsule (Immediate- and extended-release)
Pharmacological class Dual-action Beta-blocker (Nonselective beta-blocker with alpha1-antagonist)
Origin Synthetic compound

Carvicor is a prescription-only medicine that contains the active pharmaceutical ingredient, Carvedilol, a synthetic compound utilized in the management of cardiovascular issues. This drug is generally provided as a solid preparation for oral administration, typically available as a tablet or a capsule.


What Pharmacological Class Does Carvedilol Belong To?

Carvedilol belongs to the therapeutic class known as beta-blockers, or beta-adrenergic blocking agents, and is clinically recognized for its unique dual-action capability. Carvedilol is specifically classified as an Adrenergic alpha-Antagonist and beta-Adrenergic Blocker. This classification signifies that Carvedilol modulates signals affecting both the heart and the blood vessel walls. This compound is a racemic mixture, with both its R(+) and S(-) molecular forms contributing to its overall dual activity profile. The drug works by reducing peripheral vascular resistance through these combined mechanisms.


General Purpose of This Dual-Action Medicine

The general purpose of Carvicor is to ease the strain on the heart muscle and improve circulatory efficiency in adults with cardiovascular conditions. This therapeutic effect is achieved through its dual mechanism, which promotes a slower, more stable heart rate through beta-blockade while facilitating peripheral vasodilation—the relaxation and widening of the small arteries—through its alpha-1-adrenergic antagonist action. By lowering circulatory resistance and controlling the heart rate, the drug supports heart function and reduces overall workload, serving as a medication for maintaining cardiovascular stability.

What side effects are possible with Carvicor?

Possible Side Effects and Safety Information

The safety profile for Carvicor (Carvedilol) is based on official government regulatory documents, classifying all documented adverse reactions according to frequency and the body system affected.

Adverse reactions are classified according to regulatory standards:

  • Very Common (Affecting 1 in 10 or more people): Dizziness, headache, fatigue (asthenia), and hypotension (low blood pressure) are commonly noted, particularly during the initial phase of treatment. Worsening of heart failure may also be documented as very common, especially during dose increases.
  • Common: Bradycardia (slow heart rate), oedema (fluid retention), weight increase, nausea, vomiting, diarrhoea, and sleep disorders are documented in the Common category.

The official label also documents safety considerations for specific populations. Older adults may experience dizziness and syncope more frequently. Use of the medicine is contraindicated in individuals with severe hepatic impairment. In patients with diabetes, the medication may mask or obscure the characteristic symptoms of acute hypoglycemia.

Serious adverse reactions, though typically rare, are explicitly documented in regulatory information. These include second- or third-degree heart block, acute renal failure, and severe cutaneous reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile of Carvicor by the risk of several severe, potentially life-threatening clinical manifestations, requiring immediate attention. Overdose, particularly when involving higher than recommended doses or drug misuse, has been associated with serious, life-threatening ventricular arrhythmias, including Torsades de Pointes and prolongation of the QT/QRS interval, which may lead to sudden death.

Clinical Manifestations of Overdose

Overdose can affect multiple physiological systems, presenting with:

  • Severe Cardiac Events: Irregular or rapid heartbeat, fainting, cardiac arrest.
  • Central Nervous System (CNS) Depression: Stupor, depressed consciousness, and respiratory depression (shallow or ineffective breathing).
  • Gastrointestinal Complications: Severe constipation, paralytic ileus, or urinary retention.

Seeking Emergency Medical Help

Immediate emergency medical attention must be sought if any signs of overdose are observed, such as fainting, unresponsiveness, or a noticeably irregular heartbeat. Patients who have taken an overdose generally require prolonged medical monitoring, often for a period of at least 48 hours.

Population-Specific Risk

Regulatory labeling specifies that infants under two years of age are considered a high-risk population in the event of accidental exposure or overdose, due to increased susceptibility to serious heart and breathing problems.

Therapeutic Uses of Carvicor

What Carvicor Treats: Main Uses and Benefits

Carvicor (Carvedilol) is used alone or with other medications to address three key therapeutic areas: chronic heart failure, essential hypertension (high blood pressure), and stabilization following a heart attack in clinically stable patients. The medication is relevant for easing symptoms associated with cardiovascular functional stress, particularly those related to systemic imbalance and heightened physiological activity.

It is commonly applied in clinical settings that involve chronic, disruptive symptom patterns, such as the long-term management of heart failure (including mild to severe cases). The use of this medication helps support general well-being and functional stability.

“This therapeutic approach supports patients during episodes of heightened discomfort and is considered relevant for easing the overall symptom burden.”

Quick Fact: Relief for Circulatory Strain


Therapeutic Contexts

Carvicor is commonly used as part of the long-term management of chronic heart failure. For patients with a weakened heart, the medication may assist with maintaining functional stability. It is also applied in the treatment of essential hypertension, where its use contributes to easing the overall symptom load and helps improve day-to-day comfort. Furthermore, its use is considered relevant in the critical clinical scenario of left ventricular dysfunction following a heart attack, providing supportive relief that assists with maintaining functional stability in the body.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Scope

Carvicor is officially approved for use in adults (18 years of age and older), including the older adult population, for the labeled conditions. However, regulatory documents establish mandatory restrictions and absolute prohibitions based on specific physiological states and coexisting health conditions.

Contraindicated Populations (Must Not Use): Carvicor is strictly contraindicated in patients with severe hepatic impairment due to increased drug levels. Use is also prohibited in individuals with bronchial asthma or related bronchospastic conditions. Absolute prohibition also applies to acute or severe cardiac conditions, including cardiogenic shock, severe bradycardia, Second- or Third-Degree AV Block, and Sick Sinus Syndrome (unless a permanent pacemaker is in place).

Age and Reproductive Limitations:

  • Pediatric Use: Safety and efficacy have not been established in children and adolescents under 18 years of age.
  • Pregnancy and Lactation: Use during pregnancy and breastfeeding is generally not recommended unless the potential benefit is determined to outweigh the risk, as per official labeling.

Conditional Use (Caution Required):

  • Patients with non-allergic bronchospasm (COPD) require caution, and use should be avoided unless necessary. Additional caution is required for patients with Diabetes Mellitus (due to potential masking of hypoglycemia) and Peripheral Vascular Disease.

What should I know about interactions with other medicines?

The regulatory interaction profile for Carvicor (Carvedilol) is defined by pharmacokinetic and pharmacodynamic constraints, with several formal restrictions stated in official documents.

Official Restrictions and Contraindications

Use in patients with severe hepatic impairment is a formal contraindication due to the risk of a 4- to 7-fold increase in Carvedilol plasma exposure. Concomitant use of Monoamine Oxidase Inhibitors (MAOIs), excluding MAO-B inhibitors, is also contraindicated due to the risk of severe additive effects on blood pressure and heart rate.

Pharmacokinetic and Transporter Effects

Pharmacokinetic interactions involve the CYP450 enzyme system and the P-glycoprotein (P-gp) transporter. Enzyme inhibitors of CYP2D6 (such as Fluoxetine) are expected to increase the concentration of the R(+) enantiomer. In contrast, inducers like Rifampin are documented to significantly reduce Carvedilol plasma exposure by approximately 70%. Carvedilol also inhibits P-gp, resulting in increased Cyclosporine concentrations.

Pharmacodynamic and Substance Interactions

Pharmacodynamic interactions require monitoring when combined with Digitalis Glycosides (Digoxin) and Calcium Channel Blockers (Verapamil, Diltiazem) due to the synergistic potential to slow heart rate and conduction. When discontinuing combined therapy with Clonidine, the beta-blocker must be discontinued first. For heart failure patients, a timing rule requires taking the medication with food to slow the absorption rate and mitigate orthostatic effects. The regulatory label also notes that Carvedilol may potentiate the effects of alcohol.

Mechanism of Action

The mechanism of Carvicor (Carvedilol) is defined by a dual-action pharmacological profile that influences both myocardial activity and peripheral circulatory resistance, along with non-receptor-mediated effects.

Modulation of Cardiac Contraction and Rate

This domain covers the drug's action on beta1 and beta2 adrenergic receptors, which primarily reside in the heart. The active mathbfS(-) enantiomer blocks these receptors, inhibiting the signaling of endogenous catecholamines like norepinephrine and epinephrine. This molecular action slows the heart's electrical rhythm (negative chronotropy) and decreases the force of muscle contraction (negative inotropy).

Peripheral Vascular Tone Adjustment

This mechanism is driven by the antagonism of alpha1 adrenergic receptors on the walls of peripheral blood vessels. By blocking these receptors, Carvicor prevents the signals that cause vasoconstriction (vessel narrowing), leading to the relaxation and widening of the arteries (vasodilation). This physical change directly decreases the overall systemic vascular resistance (afterload), thereby decreasing the resistance against which the ventricles eject blood.

Non-Receptor-Mediated Cellular Effects

Beyond receptor blockade, Carvicor possesses antioxidant properties due to its chemical structure, which enable it to scavenge harmful oxygen free radicals. This non-receptor-mediated activity reduces oxidative stress and influences cellular integrity within the myocardial and vascular tissues.

Dosage and Administration Information

How to Use Carvicor: Official Administration Guidelines

Carvicor (Carvedilol) is administered according to an established protocol focusing on oral intake, specific frequency, and timing relative to meals. The medicine is available as an Immediate-Release (IR) tablet in strengths such as 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg, and as an Extended-Release (ER) capsule in strengths including 10 mg, 20 mg, 40 mg, and 80 mg.


Official Administration Protocol

The fundamental condition for using both the IR tablet and the ER capsule is that they must be taken with food. This timing is a standard requirement for administration. The frequency of dosing differs by formulation: IR tablets are taken twice a day, while ER capsules are taken once a day.


Dosing and Adjustment Requirements

Treatment is initiated with the lowest available dose, such as 3.125 mg for the IR tablet in Heart Failure. The dosage must be individualized and increased gradually (titrated) over time, with the rate of adjustment specifically defined. For chronic heart failure, for example, dose increases should not occur at intervals shorter than two weeks. The maximum maintenance dose for the IR tablet is typically 25 mg twice daily, but can be up to 50 mg twice daily for certain high-weight heart failure patients.

Procedural Conditions

Carvicor is typically intended for long-term use. Therapy must never be stopped abruptly; instead, the dose must be slowly tapered down. The ER capsule should not be crushed or chewed, but may be opened and sprinkled onto a small amount of soft food (like applesauce) for immediate consumption. If a dose is missed, only the next scheduled dose should be taken, without doubling up.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Carvicor

Evidence for Use in Chronic Heart Failure

Research for Carvicor in chronic heart failure conditions included large, international Randomized Controlled Trials (RCTs). These studies involved adult patients, typically those with established heart failure and reduced pumping ability of the heart (reduced Left Ventricular Ejection Fraction, or LVEF). Researchers followed these groups to compare long-term outcomes, including all-cause mortality and the rate of hospitalization related to heart problems (as reported in regulatory documentation).

The findings from these major trials documented measurements of all-cause mortality and heart failure hospitalization rates in the studied populations. Studies also monitored and documented changes in objective measurements of heart function, such as the LVEF, with the aim of documenting how the heart's structure and function evolved during the study periods. This body of evidence is part of the overall research base for conditions characterized by functional limitations and periods of heightened symptom activity.

Evidence for Use Following a Heart Attack

Carvicor was studied for use in patients who had recently survived a heart attack and were deemed clinically stable, particularly those who showed evidence of Left Ventricular Dysfunction (LVD). The studies primarily examined long-term outcomes such as all-cause mortality and rehospitalization due to cardiovascular causes in this specific post-heart attack patient group. Research indicates that the observations concerning major cardiovascular events were mainly reported in the population with reduced LVEF (pumping function below 40%).

What remains less studied is the observation of outcomes with Carvicor in post-MI patients who have a preserved LVEF (pumping function above 50%). Research in this area is limited, and the primary trial results apply only to the specific patient population studied, which focused on those with existing LVD after the event.

What the Research Landscape Suggests Is Still Uncertain

Despite the existing body of high-quality research, some aspects of Carvicor's research landscape still lack robust data. Limited comparative evidence is available in modern, head-to-head trials against newer therapeutic classes for reducing cardiovascular events in uncomplicated essential hypertension.

Studies help show what has been observed so far, but research does not provide individual predictions about whether a patient will respond similarly to the group patterns observed. The study results reflect the specific conditions under which they were conducted, meaning findings describe group patterns, not personal outcomes. Finally, evidence on specific health measures for patients with preserved LVEF following a heart attack is limited, as the main trial focused on those with reduced function.

Key Studies & References

  1. Clinical Guideline: Chronic Heart Failure in Adults: Diagnosis and Management (Representative Guideline Source)

Frequently Asked Questions (FAQ)

Common questions about Carvicor (FAQ)


Q: How quickly does Carvicor usually start to work?

A: According to official product information, the full blood pressure-lowering effect was typically observed in studies between 7 to 14 days after starting therapy or changing the dose. For heart failure, official guidelines state that the dosage titration occurs slowly, often over intervals of at least two weeks.


Q: Can Carvicor be taken with over-the-counter pain relievers?

A: Regulatory documents indicate that combining Carvicor with non-steroidal anti-inflammatory drugs (NSAIDs) may be associated with a reduction of the blood pressure-lowering effect. Additionally, common cold and flu medicines that contain decongestants (sympathomimetic agents) may oppose the effects of Carvicor by potentially raising blood pressure.


Q: Does Carvicor interact with supplements like magnesium or potassium?

A: Official information indicates that mineral supplements, including those containing magnesium and potassium, may decrease the amount of Carvicor that the body absorbs. If these supplements are taken alongside Carvicor, official documents describe a risk of reduced absorption of Carvicor.


Q: Is Carvicor known to interact with alcohol?

A: Yes, official regulatory documents state that Carvicor and alcohol can have additive effects in lowering blood pressure. Official documents state that the combination may lead to an increased potential for symptoms such as dizziness or fainting, particularly when first starting treatment.


Q: Does Carvicor have any warnings for people with liver or kidney issues?

A: Official guidance indicates that Carvicor is formally prohibited (contraindicated) for use in patients with severe hepatic (liver) impairment. Although the drug is mostly processed by the liver, official literature also recommends using caution in people with kidney impairment due to a potential for increased drug concentration.


Q: How long do I need to take Carvicor for?

A: Carvicor is typically described in regulatory documents as a medication intended for long-term use for its approved conditions. Treatment must not be stopped suddenly; if discontinuation is required, regulatory instructions state that the dosage is typically tapered over one to two weeks.


Q: What happens if a dose of Carvicor is missed?

A: If a dose is missed, regulatory instructions advise taking only the next scheduled dose. It is noted in official documentation that the dose should not be doubled to try and make up for the missed one.


Q: Is Carvicor taken once or twice a day?

A: The official administration guidelines describe different dosing frequencies depending on the formulation. The immediate-release tablet is generally taken twice a day, while the extended-release capsule is typically taken once a day, as detailed in the official administration guidelines.


Q: Is Carvicor a blood pressure medicine?

A: Yes, according to its official indications, Carvicor is used for the treatment of high blood pressure (hypertension). It is also used to manage chronic heart failure and left ventricular dysfunction following a heart attack.


Q: Do most people feel tired when taking Carvicor?

A: Official regulatory information lists fatigue (asthenia) as a very common adverse reaction, meaning it affects 1 in 10 people or more. This feeling is noted particularly during the initial phase of treatment for heart failure.


Q: Are there certain foods or drinks to avoid while using Carvicor?

A: Official administration instructions emphasize that the medicine is to be taken with food to slow its absorption and reduce the risk of orthostatic effects (dizziness when standing up). However, no specific foods or drinks are formally restricted in the main regulatory label.


Q: How is Carvicor different from other similar heart medicines?

A: Official texts describe Carvicor as unique because of its dual-action profile, which is characteristic of the drug. It is a beta-blocker that slows the heart rate but also blocks alpha-1 receptors, which helps relax and widen the blood vessels to lower resistance.


Q: Can Carvicor cause weight gain?

A: Yes, official regulatory documents list weight increase as a common adverse reaction associated with the use of Carvicor. This finding was observed in clinical studies, particularly for patients treated for heart failure.


Q: Does Carvicor affect cholesterol levels?

A: Official warnings for the beta-blocker class suggest these types of agents may alter serum lipid profiles. This may include changes in cholesterol and triglyceride levels, which requires monitoring.


Q: How is Carvicor processed by the body?

A: According to the official clinical pharmacology information, Carvicor is rapidly absorbed from the gastrointestinal system and then undergoes extensive breakdown in the liver. It is primarily eliminated from the body via the liver.


Q: What should I do if I think I'm having a side effect from Carvicor?

A: Official documentation directs patients to seek medical advice for adverse reactions. Regulatory information also provides contact details for patients to report suspected side effects to the governing regulatory agency.


Q: Is Carvicor safe to take with common cold or flu medications?

A: Regulatory warnings specifically caution against combining Carvicor with sympathomimetic agents, which are often found in cold and flu remedies as decongestants. This combination may lead to an increase in blood pressure.


Q: What evidence supports the use of Carvicor for its approved conditions?

A: Official regulatory summaries of clinical studies confirm that Carvicor reduced the risk of all-cause mortality and heart failure hospitalization in patients with chronic heart failure. It also documented a reduction in mortality in post-heart attack patients who had left ventricular dysfunction.


Q: Are there any demographic groups where Carvicor is less studied?

A: The regulatory summary of clinical trials notes that evidence is limited for a specific patient group: individuals who have experienced a heart attack but have preserved pumping function (Left Ventricular Ejection Fraction above 50%).


Q: Can Carvicor affect my sleep?

A: Yes, official regulatory documents list sleep disorders as a common adverse reaction that was reported in clinical trials involving Carvicor.


Q: Does the time of day matter when taking Carvicor?

A: Official administration guidelines state the emphasis is on taking the medicine with food, regardless of the time of day, to reduce the rate of absorption. This is done to mitigate the risk of dizziness upon standing.


Q: Can Carvicor cause problems with sexual function?

A: Official regulatory documents list sexual dysfunction as an infrequent adverse reaction. It was observed in clinical trials, occurring in less than 2% of the patients studied.


Q: Are there generic versions of Carvicor available?

A: Yes, the active ingredient in Carvicor is Carvedilol, and official regulatory resources confirm that generic versions containing Carvedilol have received regulatory approval and are available for prescription.


Q: What is the maximum recommended dose of Carvicor?

A: The maximum recommended maintenance dose is defined by the condition being treated. For some conditions like hypertension, the maximum dose for the immediate-release tablet is 50 mg daily. Higher doses have been administered in clinical studies for specific, higher-weight heart failure patient groups.


Q: What should I know about Carvicor before a surgery?

A: Regulatory guidance includes a warning for patients undergoing major surgery. The effects of the beta-blocking class of drugs may impair the heart’s ability to respond to a surgical stressor. Regulatory guidance includes a warning that patients should ensure the surgical team is informed they are taking this medicine.

How should Carvicor be stored and disposed of?

How to Store and Dispose of Carvicor?

Carvicor (carvedilol) tablets require storage under specific conditions defined in regulatory labeling to maintain product stability.

Storage Requirements

The medication must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product must be protected from moisture and dispensed in a tight, light-resistant container. To prevent exposure to humidity, storage in areas like the bathroom is not advised. As a mandatory requirement, all medicine must be kept out of the reach of children.

Disposal Instructions

When the tablets are expired or no longer needed, disposal must follow official guidelines. The medicine should be discarded in accordance with local regulations or via an authorized drug take-back program. It is explicitly required not to flush this product down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Carvicor found in:

A-Z Index: